A Multicenter Uncontrolled Study of Sorafenib in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma.

Trial Profile

A Multicenter Uncontrolled Study of Sorafenib in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma.

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Jun 2014

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Renal cancer
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Bayer
  • Most Recent Events

    • 24 Sep 2008 Actual end date (Sep 2008) added as reported by CT.gov
    • 24 Sep 2008 Status changed from active, no longer recruiting to completed as reported by CT.gov
    • 25 Jan 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top